Evidence map›Paper›PMID 36786993›Full record

ArticleDoklady. Biochemistry and biophysics2022

Transcriptome of Lung Cancer Cells Resistant to the Cytotoxic Activity of Macrophages.

O V Kovaleva, P A Podlesnaya, M V Vasileva, P B Kopnin, A S Balkin, A O Plotnikov, N E Kushlinskii, A N Gratchev

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

O V KovalevaBlokhin National Medical Research Center of Oncology, Moscow, Russia. ovkovaleva@gmail.com.
P A PodlesnayaBlokhin National Medical Research Center of Oncology, Moscow, Russia.
M V VasilevaBlokhin National Medical Research Center of Oncology, Moscow, Russia.
P B KopninBlokhin National Medical Research Center of Oncology, Moscow, Russia.
A S BalkinInstitute for Cellular and Intracellular Symbiosis of the Ural Branch of the Russian Academy of Sciences, Orenburg, Russia.
A O PlotnikovInstitute for Cellular and Intracellular Symbiosis of the Ural Branch of the Russian Academy of Sciences, Orenburg, Russia.
N E KushlinskiiBlokhin National Medical Research Center of Oncology, Moscow, Russia.
A N GratchevBlokhin National Medical Research Center of Oncology, Moscow, Russia.
National Medical Research Center of Cardiology · RUInstitute of Cellular and Intracellular Symbiosis · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of the immune system in tumor progression has been the subject of research for more than 100 years since Paul Ehrlich hypothesized that the presence of the immune system limits the occurrence of cancer. One of the mechanisms hindering the initiation and progression of the tumor is the cytotoxic activity of macrophages; however, in some cases, it is not sufficient to control tumorigenesis. This may be due to both the development of resistance of tumor cells to the antitumor activity of macrophages and the development of a tolerant phenotype of macrophages that do not have sufficient antitumor activity. In this work, the lung cancer cells resistant to the cytotoxic action of macrophages were obtained and characterized for the first time, and the genes associated with the observed changes were identified. Understanding the mechanisms of resistance of tumor cells to the cytotoxic activity of macrophages and the peculiarities of its manifestation in a tumor environment is critically important for improving the effectiveness of the existing methods of cancer treatment and developing novel methods for tumor immunotherapy.

Indexed as

Antineoplastic AgentsLung NeoplasmsHumansImmunotherapyMacrophagesTranscriptomeAntineoplastic Agentscytotoxicitymacrophagenon-small cell lung cancerRNA-seqtolerance

Identifiers

PMID36786993
OpenAlexW4320709078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.